Stable and soluble antibodies inhibiting TNFα
US11578123B2 · kind B2 · utility
0Cited by
61References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 12, 2018 |
| Grant date | Feb 14, 2023 |
| Priority date | — |
| Expiry date | Sep 12, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. The antibodies are designed for the diagnosis and/or treatment of TNF-mediated disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of the antibodies in medicine are also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.